Ansomone is synthetic Human Growth Hormone that is a white lyophilized powder developed by the Recombinant DNA technology by genetic engineering the E. Coli expression system. It consists of 191 amino acids and takes the structure of the natural human growth hormone somatotropin. It is used to treat deficiency in natural growth hormone, kidney failure and turners syndrome in females.
Ansomone is taken in the form of injections which are administered subcutaneously or intramuscularly. Once in the body, it is absorbed into the bloodstream with maximum plasma concentrations occurring after 3 to 5 hours following injection. Ansomone clearance is estimated to be between 2 and 3 hours after plasma peak concentrations and it is eliminated via the kidneys and liver.
Once Ansomone is in the body, via various regulatory mechanisms, it binds to growth hormone receptors where it promotes lipid production by breakdown of lipids stored in adipocytes, increased glucose production by mediating breakdown of glycogen in hepatocytes, increased amino acid transport to the muscle cells, mediating chondrocyte clonal expression with increase in there proliferation and differentiation, stimulating proliferation and differentiation of osteoblast which promote linear growth and development of bones, increased calcium and phosphorus absorption and increased phosphorus retention by the kidneys. Accelerating wound healing process by stimulating the proliferation and release of inflammatory cells, lymphocytes and macrophages which fight infection, treating burns and grafted tissues by increases proliferation and differentiation of macrophages, fibroblasts and collagenocytes, reversing the negative effect of nitrogen imbalance in the body caused by wounds and surgery. Reducing the occurrence of cardiovascular diseases by promoting proper lipoprotein metabolism which helps in decreasing the overall concentration of free cholesterol and low-density lipoproteins in the plasma, promoting the synthesis of cardiocytes improving the cardiac muscle contraction.
Growth hormone deficiency that results in growth failure in children, fractured bone healing, burning of excess fat in obese individuals, wound healing, treatment of cardiovascular diseases, increased muscle strength and development for bodybuilding, erectile dysfunction and increase in libido, elevation of mood and cognitive function, improved sleep for sleep deprivation, improved immune function and cell protection, bone growth and mass.
A vial with Ansomone powder should be mixed with 1ml of sterile water and injected once completely dissolved depending on the indication and prescription.
Pregnant and breastfeeding mothers, cancer patients, patients with severe infection and patients with a closed epiphysis should not use Ansomone.
• For diabetic patients, the dose for diabetic drugs should be adjusted during the growth hormone therapy.
• The dose of adrenocorticotropic hormone for patients with the hormone deficiency should be adjusted to prevent inhibition of Ansomone function.
• Glucose levels should be monitored during the therapy period as it is associated with increased insulin production.
• Thyroid hormone and functions should be monitored during Ansomone administration as it tends to cause hypothyroidism.
• Overdosing should be avoided as it can lead to hypoglycaemia, hyperglycaemia and acromegaly.
Ansomone vials come in different sizes which include 2IU, 4IU, 4.5IU, 6IU, 10IU and 16IU vials depending on the dosage and indication.
Ansomone should be kept below 8 degrees Celsius away from sunlight and the mixed solution for injection should be stored under the same conditions for not more than 48 hours.